My posts are strictly personal, not reflective of positions or policies of Insilico Medicine, which disclaims any responsibility for my individual statements.
Not enough data
Not enough data
Alex Zhavoronkov's coverage primarily focuses on the intersection of technology, healthcare, and pharmaceuticals. His interest in longevity biotechnology, AI in healthcare, drug discovery, and medical breakthroughs suggests a strong emphasis on innovative developments within these fields.
Given the specific nature of his article titles and topics covered, Alex would likely be interested in pitches that offer expert insights into cutting-edge technological advancements or scientific breakthroughs related to longevity biotechnology and artificial intelligence within the healthcare and pharmaceutical sectors.
As he often cites data and covers industry-specific events, potential sources should possess deep knowledge or involvement within these specialized areas to provide credible commentary. Furthermore, given his broad geographic focus (as no specific region is mentioned), globally relevant perspectives are likely to capture his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Meta released its most capable open source LLM, Llama 3, which outperforms in most benchmarks. Here is what you need to know.
The Altmetric Attention Score measures the popularity of scientific articles. Here are 5 practical tips on how to boost your research paper’s visibility and score.
Bryan Johnson is making headlines in tabloid and serious media around the world promoting his longevity regimen. What do serious scientists think about him?
2024 will be a pivotal year for AI Drug Discovery (AIDD). Here are 5 Industry predictions from the industry insider perspective
Silicon Valley's timeline for “solving” human health is dangerously optimistic, but AI is quietly breaking pharma's biggest bottleneck.
By: Kristen Fortney, Man Zhang, Qian Wang, Yuelei Shen, Alex Aliper, Yujie Liu, Wenbin Hou, Dominika Wilczok, Richard A. Miller, Alex Zhavoronkov
Abstract Although aging is increasingly recognized as a key factor in chronic disease management, preclinical drug development rarely incorporates direct assessments of lifespan.
